Confusing Terminology-Neuroleptic Malignant Syndrome vs Malignant Hyperthermia-Reply.

Philippe Damier
Philippe Damier
Rush University Medical Center
United States

JAMA Neurol 2017 Aug;74(8):1013

Department of Neurology, Ibn Sina Hospital, Sabah Medical Region, Kuwait.

Download full-text PDF

Source Listing

Still can't find the full text of the article?

Sign up to send a request to the authors directly.
August 2017
15 Reads

Publication Analysis

Top Keywords

malignant syndrome
syndrome malignant
malignant hyperthermia-reply
terminology-neuroleptic malignant
confusing terminology-neuroleptic

Similar Publications

Palliation of Brain Metastases: Analysis of Prognostic Factors Affecting Overall Survival.

Indian J Palliat Care 2018 Jul-Sep;24(3):308-312

Department of Radiotherapy, SMS Medical College and Attached Group of Hospitals, Jaipur, Rajasthan, India.

Context: Brain metastasis is one of the most feared complications of cancer that poses significant mortality and morbidity in patients with advanced cancer. The incidence is rising because of greater use of magnetic resonance imaging and spectroscopy; and increased survival from recent advances in immunotherapy and modern radiotherapy techniques. Despite all, the prognosis remains poor. Read More

View Article
August 2018
3 Reads

Accuracy of coronary artery calcium scoring with tube current reduction by 75%, using an adaptive iterative reconstruction algorithm.

Br J Radiol 2018 Apr 10;91(1084):20170678. Epub 2018 Jan 10.

1 Department of Radiology, Charité - Universitätsmedizin Berlin, Campus Charité Mitte , Charité - Universitätsmedizin Berlin, Campus Charité Mitte , Berlin , Germany.

Objective: To assess the accuracy of an iterative reconstruction (IR) technique for coronary artery calcium scoring with reduced radiation dose.

Methods: 163 consecutive patients underwent twofold scanning by 320-row detector CT at 120 kVp. A low-dose scan at 25% tube current but with standard scan length (14 cm) was followed by a standard dose scan with routine tube current but reduced scan length (10 cm). Read More

View Article
April 2018
10 Reads
1.53 Impact Factor

Decline and changing profile of hepatitis delta among injection drug users in Spain.

Antivir Ther 2018 ;23(1):87-90

Infectious Diseases Unit, La Paz University Hospital & Autonomous University, Madrid, Spain.

Background: Roughly 15 million people worldwide have hepatitis delta, the most severe form of chronic viral hepatitis that often leads to cirrhosis and liver cancer. Injection drug users (IDUs) are the largest HDV reservoir. Their resurgence in North America and Europe may represent a new opportunity for HDV to spread more widely. Read More

View Article
January 2018
21 Reads
3.02 Impact Factor

Blood-based biomarkers of adverse perinatal outcomes in maternal obesity.

J Matern Fetal Neonatal Med 2017 Dec 12;30(24):2991-2997. Epub 2017 Jan 12.

c Centro de Neurociencias y Unidad de Investigación Clínica , Instituto de Investigaciones Científicas y Servicios de Alta Tecnología (INDICASAT AIP) , Clayton , Panamá.

Objective: Increasing maternal weight has been shown to predict adverse perinatal outcome, including increases in the relative risk of fetal death, stillbirth, neonatal death, perinatal death and infant death. In order to better understand the pathophysiological factors associated with obesity during pregnancy, the role of biomarkers associated with adverse outcomes in obese pregnant women is under investigation. The purpose of this review study was to examine potential biomarkers that could serve as effective screening strategies in obese pregnant women to reduce fetal and neonatal morbidity, as well as maternal morbidity. Read More

View Article
December 2017
4 Reads

Celecoxib sensitizes imatinib-resistant K562 cells to imatinib by inhibiting MRP1-5, ABCA2 and ABCG2 transporters via Wnt and Ras signaling pathways.

Leuk Res 2015 Jul 6;39(7):696-701. Epub 2015 Apr 6.

Department of Animal Biology, University of Hyderabad, Hyderabad 500046, Telangana, India. Electronic address:

Imatinib mesylate, a tyrosine kinase inhibitor, is very effective in the treatment of chronic myeloid leukemia (CML). However, development of resistance to imatinib therapy is also a very common mechanism observed with long-term administration of the drug. Our previous studies have highlighted the role of cyclooxygenase-2 (COX-2) in regulating the expression of multidrug resistant protein-1 (MDR1), P-gp, in imatinib-resistant K562 cells (IR-K562) via PGE2-cAMP-PKC-NF-κB pathway and inhibition of COX-2 by celecoxib, a COX-2 specific inhibitor, inhibits this pathway and reverses the drug resistance. Read More

View Article
July 2015
11 Reads
13 PubMed Central Citations(source)
2.35 Impact Factor